Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort

Multiple Sclerosis Journal

Volumn 19, Issue 11, 2013, Pages 1533-1538

  Olsson, Tomas ^a   Achiron, Anat ^b   Alfredsson, Lars ^c   Berger, Thomas ^d   Brassat, David ^e   Chan, Andrew ^f   Comi, Giancarlo ^g   Eraksoy, Mefkure ^h   Hegen, Harald ^d   Hillert, Jan ^a   Jensen, Poul Erik Hyldgaard ⁱ   Moiola, Lucia ^g   Myhr, Kjell Morten ^j   Oturai, Annette ⁱ   Schippling, Sven ^k,l   Siva, Aksel ^h   Sorensen, Per Soelberg ⁱ   Trampe, Anne Kathrin ^f   Weber, Thomas ⁿ   Potts, James ^o   Plavina, Tatiana ^o   Paes, Dominic ^o   Subramanyam, Meena ^o   Wiendl, Heinz ^p   Dib, Hussein ^q   Üren, Deniz ^q   Hemmer, Bernhard ^r   Buck, Dorothea ^m   more..

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b TEL AVIV UNIVERSITY   (Israel)

^c KAROLINSKA INSTITUTE   (Sweden)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e UNIVERSITÉ DE TOULOUSE   (France)

^f ST JOSEF HOSPITAL   (Germany)

^g VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^h ISTANBUL UNIVERSITY   (Turkey)

ⁱ Rigshospitalet   (Denmark)

^j HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^k UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^l UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^m TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁿ UNIVERSITY OF HAMBURG   (Germany)

^o BIOGEN   (United States)

^p UNIVERSITY OF MÜNSTER   (Germany)

^q Gen Pharmaceuticals   (Turkey)

^r Germany 3 Munich Cluster for Systems Neurology   (Germany)

more..

Author keywords

anti JCV antibodies; antibody prevalence; brain infection; epidemiology; immunosuppressant therapy; infection risk; international study; JC virus; Multiple sclerosis; natalizumab; STRATIFY JCV

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; JC VIRUS ANTIBODY; NATALIZUMAB; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; AUSTRIA; CROSS-SECTIONAL STUDY; DENMARK; DRUG EXPOSURE; FEMALE; FRANCE; GERMANY; HUMAN; ISRAEL; ITALY; JC VIRUS; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NORWAY; PREVALENCE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SEROPREVALENCE; SWEDEN;

ANTI-JCV ANTIBODIES; ANTIBODY PREVALENCE; BRAIN INFECTION; EPIDEMIOLOGY; IMMUNOSUPPRESSANT THERAPY; INFECTION RISK; INTERNATIONAL STUDY; JC VIRUS; MULTIPLE SCLEROSIS; NATALIZUMAB; STRATIFY-JCV;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; CHILD; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JC VIRUS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; POLYOMAVIRUS INFECTIONS; PREVALENCE; SEX DISTRIBUTION; YOUNG ADULT;

EID: 84884552568     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513477925     Document Type: Article

References (10)

1. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: Clinical features and pathogenesis. Lancet Neurol. 2010 ; 9: 425-437
2. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab- associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012 ; 366: 1870-1880
3. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: Implications for PML risk stratification. Ann Neurol. 2010 ; 68: 295-303
4. Bozic C, Richman S, Plavina T, et al. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY-1. Ann Neurol. 2011 ; 70: 742-750
5. Bozic C, Richman S, Plavina T, et al. Anti-JCV antibody prevalence in patients with relapsing multiple sclerosis receiving or considering treatment with natalizumab: baseline results of STRATIFY-2. Neurology. 2012 ; 78 :
6. Trampe AK, Hemmelmann C, Stroet A, et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology. 2012 ; 78: 1736-1742
7. Outteryck O, Ongagna JC, Duhamel A, et al. Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy. J Neurol. 2012 ; 259: 2293-2298
8. Moiola L, Sangalli F, Martinelli F, et al. Prevalence of anti-JCV antibodies in a cohort of natalizumab-treated multiple sclerosis patients from Italy. Neurology. 2011 ; 76 :
9. Subramanyam M, Plavina T, Simon K, et al. Factors associated with anti-JCV antibody prevalence in large cohorts of natalizumab-treated MS patients. Mult Scler. 2010 ; 16: S38 - S39
10. Achiron A, Chapman J, Doleve M, et al. Epidemiology of anti-JCV antibodies in Israeli multiple sclerosis population. American Academy of Neurology 64th Annual Meeting ; New Orleans, LA, USA ;..